Drugs / Parsatuzumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01075464 | Feb 2010 → Apr 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00909740 | May 2009 → Oct 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT01399684 | Nov 2011 → Feb 2014 | colorectal cancer | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01366131 | Jun 2011 → Feb 2013 | non-small cell lung carcinoma | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parsatuzumab | “This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6...” PMID 28275117 ↗ Mar 2017 |
| Known as | anti-EGFL7 monoclonal antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109387 ↗ |
| Known as | MEGF0444A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01366131 ↗ |
| Known as | RG-741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109387 ↗ |
| Known as | RG-7414 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109387 ↗ |
| Action | Inhibit | “Epidermal growth factor-like protein 7 inhibitor” CHEMBL2109387 ↗ |
| Modality | Monoclonal antibody | “MEGF0444A, a Human IgG1 Antibody” NCT01075464 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT00909740 ↗ |
| Target | EGFL7 | “Epidermal growth factor-like protein 7 inhibitor” CHEMBL2109387 ↗ |